EA202092271A1 - Комбинации макролидных соединений и ингибиторов контрольных точек иммунитета - Google Patents

Комбинации макролидных соединений и ингибиторов контрольных точек иммунитета

Info

Publication number
EA202092271A1
EA202092271A1 EA202092271A EA202092271A EA202092271A1 EA 202092271 A1 EA202092271 A1 EA 202092271A1 EA 202092271 A EA202092271 A EA 202092271A EA 202092271 A EA202092271 A EA 202092271A EA 202092271 A1 EA202092271 A1 EA 202092271A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
inhibitors
control points
macrolide compounds
immunity control
Prior art date
Application number
EA202092271A
Other languages
English (en)
Inventor
Ола Винквист
Original Assignee
АйЭсАр ИММЬЮН СИСТЕМ РЕГЬЮЛЕЙШН ХОЛДИНГ АБ (ПАБЛ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АйЭсАр ИММЬЮН СИСТЕМ РЕГЬЮЛЕЙШН ХОЛДИНГ АБ (ПАБЛ) filed Critical АйЭсАр ИММЬЮН СИСТЕМ РЕГЬЮЛЕЙШН ХОЛДИНГ АБ (ПАБЛ)
Priority claimed from PCT/EP2019/057364 external-priority patent/WO2019180265A1/en
Publication of EA202092271A1 publication Critical patent/EA202092271A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящим изобретением предусмотрены комбинации иммуностимулирующих макролидов с ингибиторами контрольных точек иммунитета. Комбинации обладают синергическим действием и могут применяться при лечении вирусных заболеваний и рака.
EA202092271A 2018-03-23 2019-03-25 Комбинации макролидных соединений и ингибиторов контрольных точек иммунитета EA202092271A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18163705 2018-03-23
PCT/EP2019/057364 WO2019180265A1 (en) 2018-03-23 2019-03-25 Combinations of macrolide compounds and immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
EA202092271A1 true EA202092271A1 (ru) 2021-02-01

Family

ID=61768099

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092271A EA202092271A1 (ru) 2018-03-23 2019-03-25 Комбинации макролидных соединений и ингибиторов контрольных точек иммунитета

Country Status (1)

Country Link
EA (1) EA202092271A1 (ru)

Similar Documents

Publication Publication Date Title
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201700464A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EA201790413A1 (ru) Антитела против tigit
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
BR112018016450A2 (pt) composições intensificadoras de vcn e métodos de uso das mesmas
EA201800148A1 (ru) Оспенная вакцина для лечения рака
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CY1123221T1 (el) Ενωσεις θειαζολιδιου για αντιμετωπιση ιογενων λοιμοξεων
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MX2020004914A (es) Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario.
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
EA201991927A1 (ru) Новый иммуностимулирующий макролид
EA202090270A1 (ru) Новые замещенные производные ксантина